vs
Opus Genetics, Inc.（IRD）与MESABI TRUST（MSB）财务数据对比。点击上方公司名可切换其他公司
Opus Genetics, Inc.的季度营收约是MESABI TRUST的1.1倍（$3.9M vs $3.6M），Opus Genetics, Inc.同比增速更快（-10.2% vs -95.5%），过去两年Opus Genetics, Inc.的营收复合增速更高（50.3% vs -24.1%）
Opus Genetics是一家临床阶段生物技术企业，专注开发针对遗传性视网膜疾病的靶向基因疗法，致力于为患有罕见致盲性眼部疾病的患者解决未被满足的医疗需求，核心业务为面向全球罕见病市场推进可及性治疗候选药物的研发工作。
梅萨比信托是一家总部位于美国的特许权信托机构，持有明尼苏达州梅萨比山脉铁矿开采资产的特许权权益，主要通过与铁矿石生产销售挂钩的特许权使用费获得收益，服务于全球钢铁制造市场。
IRD vs MSB — 直观对比
营收规模更大
IRD
是对方的1.1倍
$3.6M
营收增速更快
IRD
高出85.3%
-95.5%
两年增速更快
IRD
近两年复合增速
-24.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.9M | $3.6M |
| 净利润 | — | $2.8M |
| 毛利率 | — | 77.1% |
| 营业利润率 | — | — |
| 净利率 | — | 77.1% |
| 营收同比 | -10.2% | -95.5% |
| 净利润同比 | 53.0% | -96.5% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IRDMSB
| Q4 25 | $3.9M | $3.6M | ||
| Q3 25 | $3.1M | $5.6M | ||
| Q2 25 | $2.9M | $4.7M | ||
| Q1 25 | $4.4M | $6.9M | ||
| Q4 24 | $4.3M | $79.0M | ||
| Q3 24 | $3.9M | $6.5M | ||
| Q2 24 | $1.1M | $6.3M | ||
| Q1 24 | $1.7M | $6.2M |
净利润IRDMSB
| Q4 25 | — | $2.8M | ||
| Q3 25 | $-17.5M | $4.7M | ||
| Q2 25 | $-7.4M | $3.6M | ||
| Q1 25 | $-8.2M | $6.1M | ||
| Q4 24 | — | $78.3M | ||
| Q3 24 | $-7.5M | $5.4M | ||
| Q2 24 | $-7.8M | $3.5M | ||
| Q1 24 | $-7.1M | $4.7M |
毛利率IRDMSB
| Q4 25 | — | 77.1% | ||
| Q3 25 | — | 84.6% | ||
| Q2 25 | — | 76.7% | ||
| Q1 25 | — | 88.5% | ||
| Q4 24 | — | 99.1% | ||
| Q3 24 | — | 83.2% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 75.3% |
营业利润率IRDMSB
| Q4 25 | — | — | ||
| Q3 25 | -269.9% | — | ||
| Q2 25 | -309.0% | — | ||
| Q1 25 | -227.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -207.1% | — | ||
| Q2 24 | -748.9% | — | ||
| Q1 24 | -450.5% | — |
净利率IRDMSB
| Q4 25 | — | 77.1% | ||
| Q3 25 | -566.9% | 84.6% | ||
| Q2 25 | -257.5% | 76.7% | ||
| Q1 25 | -187.5% | 88.5% | ||
| Q4 24 | — | 99.1% | ||
| Q3 24 | -194.6% | 83.2% | ||
| Q2 24 | -698.3% | 55.7% | ||
| Q1 24 | -415.3% | 75.3% |
每股收益（稀释后）IRDMSB
| Q4 25 | — | — | ||
| Q3 25 | $-0.25 | — | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $-0.24 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.29 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.29 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $45.1M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $15.3M | $21.1M |
| 总资产 | $50.2M | $26.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IRDMSB
| Q4 25 | $45.1M | — | ||
| Q3 25 | $30.8M | — | ||
| Q2 25 | $32.4M | — | ||
| Q1 25 | $41.8M | — | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $36.6M | — | ||
| Q2 24 | $41.4M | — | ||
| Q1 24 | $47.2M | — |
股东权益IRDMSB
| Q4 25 | $15.3M | $21.1M | ||
| Q3 25 | $6.0M | $22.8M | ||
| Q2 25 | $17.5M | $19.6M | ||
| Q1 25 | $5.1M | $23.3M | ||
| Q4 24 | $6.7M | $95.3M | ||
| Q3 24 | $34.3M | $22.1M | ||
| Q2 24 | $40.6M | $20.7M | ||
| Q1 24 | $46.1M | $21.0M |
总资产IRDMSB
| Q4 25 | $50.2M | $26.0M | ||
| Q3 25 | $36.1M | $24.8M | ||
| Q2 25 | $38.7M | $27.4M | ||
| Q1 25 | $48.2M | $101.7M | ||
| Q4 24 | $36.9M | $100.7M | ||
| Q3 24 | $40.4M | $26.2M | ||
| Q2 24 | $44.8M | $25.1M | ||
| Q1 24 | $51.8M | $26.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-35.3M | $3.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.27× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流IRDMSB
| Q4 25 | $-35.3M | $3.5M | ||
| Q3 25 | $-6.2M | $4.4M | ||
| Q2 25 | $-10.3M | $2.1M | ||
| Q1 25 | $-9.0M | $93.9M | ||
| Q4 24 | $-25.6M | $78.2M | ||
| Q3 24 | $-5.1M | $3.8M | ||
| Q2 24 | $-7.3M | $2.5M | ||
| Q1 24 | $-5.7M | $14.6M |
现金转化率IRDMSB
| Q4 25 | — | 1.27× | ||
| Q3 25 | — | 0.92× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 15.48× | ||
| Q4 24 | — | 1.00× | ||
| Q3 24 | — | 0.71× | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | 3.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
